NASDAQ:AMED - Amedisys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$136.22 -2.51 (-1.81 %)
(As of 02/17/2019 03:40 PM ET)
Previous Close$136.22
Today's Range$134.49 - $136.76
52-Week Range$55.41 - $140.91
Volume698,499 shs
Average Volume326,981 shs
Market Capitalization$4.34 billion
P/E Ratio61.64
Dividend YieldN/A
Beta1.43
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.53 billion
Cash Flow$2.7480 per share
Book Value$15.22 per share

Profitability

Net Income$30.30 million

Miscellaneous

Employees17,900
Market Cap$4.34 billion
OptionableOptionable

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) posted its earnings results on Monday, October, 29th. The health services provider reported $0.95 EPS for the quarter, topping the Zacks' consensus estimate of $0.77 by $0.18. The health services provider earned $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The company's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.56 EPS. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Amedisys.

What price target have analysts set for AMED?

13 brokerages have issued 1 year price targets for Amedisys' shares. Their forecasts range from $63.00 to $139.00. On average, they expect Amedisys' share price to reach $111.8185 in the next twelve months. This suggests that the stock has a possible downside of 17.9%. View Analyst Price Targets for Amedisys.

What is the consensus analysts' recommendation for Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amedisys.

Has Amedisys been receiving favorable news coverage?

News coverage about AMED stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amedisys earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media headlines about the health services provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. Michael P. North, Chief Information Officer (Age 54)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.74%), Dimensional Fund Advisors LP (3.14%), Acadian Asset Management LLC (2.52%), Bank of New York Mellon Corp (1.62%), Geode Capital Management LLC (1.35%) and Northern Trust Corp (1.20%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Linda J Hall, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Which major investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Kohlberg Kravis Roberts & Co. L.P., Northern Trust Corp, Rothschild & Co. Asset Management US Inc., Dimensional Fund Advisors LP, Castleark Management LLC, Hancock Whitney Corp, First Trust Advisors LP and TD Asset Management Inc.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Which major investors are buying Amedisys stock?

AMED stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Acadian Asset Management LLC, Millennium Management LLC, Robeco Institutional Asset Management B.V., Geode Capital Management LLC, Bank of America Corp DE, Columbus Circle Investors and Meritage Portfolio Management. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $136.22.

How big of a company is Amedisys?

Amedisys has a market capitalization of $4.34 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  450 (Vote Underperform)
Total Votes:  735
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel